Comparative efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy in HR+/HR2- patients with advanced or metastatic breast cancer: a systematic review and network meta-analysis
Abstract Introduction This study aims to evaluate the clinical efficacy and safety profiles of various cyclin-dependent kinase 4/6 inhibitors(CDK4/6i) when administered alongside endocrine therapy (ET) in individuals diagnosed with advanced or metastatic breast cancer characterized by hormone recept...
Gorde:
| Egile Nagusiak: | , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BMC
2025-10-01
|
| Saila: | BMC Cancer |
| Gaiak: | |
| Sarrera elektronikoa: | https://doi.org/10.1186/s12885-025-14841-2 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|